EUCTR2021-003809-22-NO进行中（未招募）1 期
A phase II multicenter single-armed study using subject-specific minimal residual disease markers to adopt treatment after allogeneic stem cell transplantation for subjects with myelodysplastic syndrome - MDS - MDS
Karolinska University Hospital0 个研究点目标入组 200 人开始时间: 2022年8月8日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •Signed informed consent
- •Age = 18 years
- •Subjects eligible for stem cell transplantation (SCT)
- •Subjects having the disease MDS, mixed myelodysplastic/myeloproliferative syndrome or AML with myelodysplasia related dysplasia and 20-29% marrow blasts
- •All female subjects of childbearing potential have to have negative pregnancy test within 2 weeks prior to inclusion to the study
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 100
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 100
排除标准
- •No genetic aberration identified either in screening next generation sequencing panel or next generation sequencing panel performed at diagnosis
- •Uncontrolled hypertension, heart, liver, kidney related or other uncontrolled medical or psychiatric disorders
- •Mental inability, reluctance or language difficulties that results in difficulty understanding the meaning of study participation
研究者
相似试验
进行中（未招募）
1 期
MDSG-14B2Myelodysplastic syndromeCTIS2024-511651-17-00Karolinska University Hospital175
进行中（未招募）
1 期
A study using subject-specific minimal residual disease markers to adopt treatment after allogeneic stem cell transplantation for subjects with myelodysplastic syndrome - MDSMyelodysplastic syndrome (MDS)EUCTR2021-003809-22-FIKarolinska University Hospital200
已完成
不适用
Study to Evaluate the Efficacy of Lazertinib in Patients with Non-small cell lung cancer(NSCLC) Who Harboring EGFR T790M Mutation Detected by Bronchoalveolar Lavage Liquid (BALiquid)KCT0006841Konkuk University Medical Center32
进行中（未招募）
不适用
A Multi-Centre Single-Arm Phase II Study To Evaluate The Biological Effects Of Intratumoral Administration of Wild-Type Reovirus (REOLYSIN®) in Combination with Low Dose Radiation in Patients With Advanced Cancers Including Head, Neck and Esophageal Cancer.Advanced or metastatic solid tumours that are refractory to standard therapy or for which no standard curative therapy existsMedDRA version: 9.1Level: LLTClassification code 10049280Term: Solid tumourEUCTR2006-002190-49-GBOncolytics Biotech Inc40
进行中（未招募）
1 期
A medical research evaluating the safety and efficacy of two new medicines (Necitumumab and Abemaciclib), administered in combination in patients affected by a defined type of advanced lung cancer (Stage IV Non-Small-Cell Lung Cancer)on Small Cell Lung CancerMedDRA version: 19.0Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2014-005042-21-ESilly S.A.68